We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
-29.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.8M
AUM Growth
-$85.7M
Cap. Flow
-$60.4M
Cap. Flow %
-102.71%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$57.4M
2
MRSN
Mersana Therapeutics
MRSN
+$3M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 94.3%
2 Communication Services 5.42%
3 Healthcare 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHPT icon
1
ChargePoint
CHPT
$133M
$55.5M 94.3%
202,663
– –
LVO icon
2
LiveOne
LVO
$66M
$3.19M 5.42%
372,414
– –
SENS icon
3
Senseonics Holdings Inc
SENS
$254M
$164K 0.28%
7,980
– –
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
– –
-31,858
Closed -$3M
NGM
5
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-3,766,666
Closed -$57.4M

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Rho Capital Partners held 5 positions worth $58.8M, down 59% from $145M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners withdrew a net $60.4M in Q2 2022, closing 2 positions. Its most notable exit was NGM Biopharmaceuticals, Inc. Common Stock, an estimated $57.4M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 94% of assets, up from 56% a quarter earlier, followed by Communication Services and Healthcare.

  • Rho Capital Partners fully exited NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022, selling an estimated $57.4M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $58.8M portfolio in Q2 2022.
  • Rho Capital Partners opened 0 new positions and closed 2 in Q2 2022.
  • Rho Capital Partners's portfolio value fell 59% quarter-over-quarter to $58.8M.

Based on Rho Capital Partners's 13F filing for Q2 2022, filed 1 Aug 2022.